title: Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737.
abstract: Anoikis, a Bax-dependent apoptosis triggered by detachment from the extracellular matrix, is often inhibited in metastatic cancer cells. Using a couple of isogenic human colon cancer cell lines derived either from the primary tumor (SW480) or from a lymph node metastasis (SW620), we found that only SW480 cells were sensitive to anoikis. Bim upregulation but not Mcl-1 degradation was determined to be a critical factor of anoikis initiation in SW480 cells. ERK-mediated phosphorylation targets Bim for ubiquitination and proteasomal degradation. A MEK inhibitor (PD0325901) was able to increase Bim expression in SW620 cells and to sensitize these cells to anoikis. Thus, in both cell lines anoikis is under the control of proteins of the Bcl-2 family. Most interestingly, the BH3-mimetic ABT-737 was found not only to increase the level of apoptosis in suspended SW480 cells but also to sensitize SW620 cells to anoikis. Accordingly, both cell lines cultured in suspension were found to be primed for death, as determined by the detection of Bcl-2:Bim and Bcl-xL:Bim complexes. In contrast, adherent SW480 and SW620 cells were resistant to ABT-737. This indicates that, whether or not they undergo anoikis, colon cancer cells that have detached from the extracellular matrix might go through a transient state, where they are sensitive to BH3 mimetics. This would confer to compounds such as Navitoclax or ABT-199 a therapeutic window where they could have anti-metastatic potential.
authors.affiliation: Inserm U1004, Hôpital Paul Brousse, 12 Avenue Paul Vaillant-Couturier, Villejuif 94800, France.
authors.forename: A
authors.initials: A
authors.lastname: Maamer-Azzabi
authors.forename: O
authors.initials: O
authors.lastname: Ndozangue-Touriguine
authors.forename: J
authors.initials: J
authors.lastname: Bréard
mesh_terms: D023102:Anoikis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D000072224:Bcl-2-Like Protein 11; D014408:Biomarkers, Tumor / Q000378:metabolism; D001713:Biphenyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D009596:Nitrophenols / Q000494:pharmacology* / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: C501332:ABT-737; D051017:Apoptosis Regulatory Proteins; C000606775:BCL2L11 protein, human; D000072224:Bcl-2-Like Protein 11; D014408:Biomarkers, Tumor; D001713:Biphenyl Compounds; D008565:Membrane Proteins; D009596:Nitrophenols; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D013449:Sulfonamides; D048049:Extracellular Signal-Regulated MAP Kinases
references.citation: Semin Cancer Biol. 2012 Jun;22(3):194-207
references.pmid: 22406545
references.citation: Mol Cell. 2006 Mar 17;21(6):749-60
references.pmid: 16543145
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3787-92
references.pmid: 17360431
references.citation: Oncogene. 2003 Oct 2;22(43):6785-93
references.pmid: 14555991
references.citation: Cancer Cell. 2006 May;9(5):351-65
references.pmid: 16697956
references.citation: Genes Dev. 2003 Jun 15;17(12):1475-86
references.pmid: 12783855
references.citation: Science. 2001 Sep 7;293(5536):1829-32
references.pmid: 11546872
references.citation: Nat Rev Cancer. 2002 Aug;2(8):563-72
references.pmid: 12154349
references.citation: Clin Cancer Res. 2009 Oct 1;15(19):6096-105
references.pmid: 19773376
references.citation: EMBO J. 1998 Jan 15;17(2):384-95
references.pmid: 9430630
references.citation: Curr Mol Pharmacol. 2008 Nov;1(3):244-54
references.pmid: 20021437
references.citation: Cancer Cell. 2006 Nov;10(5):343-5
references.pmid: 17097553
references.citation: J Immunol Methods. 1991 Jun 3;139(2):271-9
references.pmid: 1710634
references.citation: Cell. 1994 May 20;77(4):477-8
references.pmid: 8187171
references.citation: Nature. 2005 Jun 2;435(7042):677-81
references.pmid: 15902208
references.citation: Int J Cell Biol. 2012;2012:306879
references.pmid: 22505926
references.citation: Nat Cell Biol. 2003 Aug;5(8):733-40
references.pmid: 12844146
references.citation: Methods Enzymol. 2009;463:305-28
references.pmid: 19892179
references.citation: Nat Rev Cancer. 2012 May 11;12(6):425-36
references.pmid: 22576165
references.citation: Apoptosis. 2002 Jun;7(3):247-60
references.pmid: 11997669
references.citation: Cancer Cell. 2002 Sep;2(3):183-92
references.pmid: 12242151
references.citation: Cancer Cell. 2006 Nov;10(5):389-99
references.pmid: 17097561
references.citation: Nat Med. 2013 Feb;19(2):202-8
references.pmid: 23291630
references.citation: Cancer Res. 2008 Oct 1;68(19):7985-94
references.pmid: 18829556
references.citation: Mol Cell. 2004 Dec 3;16(5):807-18
references.pmid: 15574335
references.citation: Mol Cancer Ther. 2011 Dec;10(12):2340-9
references.pmid: 21914853
references.citation: J Cell Biol. 1994 Feb;124(4):619-26
references.pmid: 8106557
references.citation: Cancer Cell. 2013 Jan 14;23(1):121-8
references.pmid: 23245996
references.citation: J Clin Invest. 2007 Jan;117(1):112-21
references.pmid: 17200714
references.citation: Ann N Y Acad Sci. 2004 Apr;1014:155-63
references.pmid: 15153430
references.citation: Cancer Res. 2001 May 1;61(9):3819-25
references.pmid: 11325858
references.citation: J Neurosci Methods. 2004 Aug 30;137(2):275-81
references.pmid: 15262071
references.citation: Curr Biol. 1999 Sep 23;9(18):1047-9
references.pmid: 10508612
references.citation: Cancer Cell. 2007 Aug;12(2):171-85
references.pmid: 17692808
references.citation: Cancer Res. 1976 Dec;36(12):4562-9
references.pmid: 1000501
references.citation: Dev Cell. 2011 Jul 19;21(1):92-101
references.pmid: 21763611
references.citation: Cell Biol Int Rep. 1981 Feb;5(2):125-32
references.pmid: 6784935
references.citation: Cancer Res. 2008 Feb 1;68(3):909-17
references.pmid: 18245494
references.citation: Mol Cell. 1999 Mar;3(3):287-96
references.pmid: 10198631
references.citation: Cancer Res. 2013 Feb 15;73(4):1340-51
references.pmid: 23243017
references.citation: J Biol Chem. 2003 May 30;278(22):19917-25
references.pmid: 12621032
references.citation: Mol Cell Biol. 2011 Oct;31(19):4036-51
references.pmid: 21746881
references.citation: Cell. 2004 Jan 23;116(2):205-19
references.pmid: 14744432
references.citation: Cancer Cell. 2006 Nov;10(5):375-88
references.pmid: 17097560
references.citation: Cancer Res. 2007 Nov 15;67(22):10744-52
references.pmid: 18006817
references.citation: Oncogene. 2008 Oct 9;27(46):6012-22
references.pmid: 18560353
references.citation: Nat Rev Cancer. 2002 Sep;2(9):647-56
references.pmid: 12209154
references.citation: J Invest Dermatol. 1989 Aug;93(2):287-90
references.pmid: 2546994
references.citation: Cell Death Differ. 2013 May;20(5):755-64
references.pmid: 23429261
references.citation: Cell Death Differ. 2005 Nov;12 Suppl 2:1473-7
references.pmid: 16247493
references.citation: Mol Cancer Ther. 2009 Dec;8(12):3173-80
references.pmid: 19934277
references.citation: J Pathol. 2000 Dec;192(4):446-54
references.pmid: 11113861
references.citation: J Biol Chem. 2011 Jul 29;286(30):26533-40
references.pmid: 21673109